Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094
- PMID: 35723890
- PMCID: PMC9631559
- DOI: 10.1182/bloodadvances.2022007724
Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094
Erratum for
-
Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.Blood Adv. 2022 Feb 22;6(4):1089-1094. doi: 10.1182/bloodadvances.2021006119. Blood Adv. 2022. PMID: 34794179 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
